Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

TORONTO, July 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin(R) development program, including the publication of two research studies on the Virulizin(R) mode of action and the issuance of a new patent for Virulizin(R) in Mexico.

"Publication of these two studies in international scientific journals adds significantly to our previous studies on Virulizin(R) anticancer mechanisms and activities," commented Dr. Aiping Young, Lorus' President and CEO. "In addition, allowance of a new patent strengthens the intellectual property position for this product, and protects the potential for expanding the use to other cancer indications in this jurisdiction."

New Virulizin(R) patent issued in Mexico

The patent, titled "Immunomodulating Compositions from Bile for the Treatment of Immune System Disorders", protects methods of treating several cancers using Virulizin(R). This is the second patent issued in Mexico for Virulizin(R), and extends patent protection for Virulizin(R) in this country to 2016. Similar patents for Virulizin(R) have also been issued in a number of other countries worldwide, including Canada, Australia, and the United States.

Virulizin(R) is currently approved for the treatment of malignant melanoma in Mexico. The new patent provides protection for the potential treatment with Virulizin(R) of additional cancers, including ovarian and lung cancers. Virulizin(R) composition, manufacturing process, and use in the treatment of cancers are also protected in Mexico under an earlier patent issued to Lorus in 2003.

Virulizin(R) has demonstrated significant anticancer activity against a wide range of human cancers in preclinical studies, and has been tested in several clinical
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
(Date:12/22/2014)... Chicago, Illinois (PRWEB) December 22, 2014 ... representing tenants and occupiers of commercial real estate, has ... two new offices in Perth and Brisbane, Western Australia, ... board of directors. , ITRA Global / ACORPP ... and totally independent consultancy company providing property services to ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
Breaking Biology Technology:Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... CHAPEL HILL, N.C., Nov. 5 As ... market, considerable efforts,are placed on strategy and ... largely focus on revenue growth and little ... launch excellence, a recent study,was conducted by ...
... Assay Designs, Inc., a leading,provider of ... life science,and translational research markets, has announced ... The agreement enables Assay Designs to,distribute approximately ... their U.S. and Canadian customers. This major ...
... N.Y., Nov. 5 Misonix, Inc.,(Nasdaq: MSON ... device,technology, which in Europe is used for the ... conditions, has entered into a new, three,year, exclusive ... Rotterdam, The Netherlands, for the distribution of the,SonaStar(TM) ...
Cached Biology Technology:New Study Provides Key Findings for Biopharma Product Launch Evaluation 2Assay Designs(TM), Inc. Announces Agreement with Abnova Corp. of Taiwan 2Misonix Announces New Distribution Agreement for The Netherlands 2Misonix Announces New Distribution Agreement for The Netherlands 3
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... 2009 Olympus, a precision technology leader, creating ... consumer electronics products, today announced the introduction of ... a customized and comprehensive system for examining high ... and express viewing modes, the software reduces the ...
... clinics the world over could benefit from new software* created ... a team of scientists has found a way to improve ... the University of Alabama at Birmingham (UAB). Pneumonia is ... years of age and poses a serious risk to elderly ...
... leap for averting natural and man-made disasters on earth. ... orbit with sensors on the ground and in the air ... give advance warnings about water contamination after a forest fire, ... flag is raised on earth, or tell people in China ...
Cached Biology News:Improved Endo Capsule Software enhances diagnostic experience 2Scientists create NICE solution to pneumonia vaccine testing problems 2Sensing disasters from space 2
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Homo sapiens MEP50 protein, mRNA...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: